FindTrial
Sign In

Ceftazidime - Avibactam ( CAZ-AVI)

DRUG4 trials

Sponsors

Pfizer, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Conditions

CRE ColonizationCarbapenem-resistant EnterobacteralesComplicated Intra-abdominal InfectionComplicated Urinary Tract InfectionComplicated Urinary Tract Infection (cUTI) Including Acute PyelonephritisLiver Transplant

Phase 3

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
CompletedNCT01595438
PfizerComplicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Start: 2012-10-31End: 2014-08-31Updated: 2017-09-06
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
CompletedNCT01599806
PfizerComplicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Start: 2012-10-31End: 2014-08-31Updated: 2017-09-06
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
CompletedNCT01644643
PfizerComplicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Start: 2013-01-31End: 2014-09-30Updated: 2017-09-29
Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation
Not yet recruitingNCT07759453
IRCCS Azienda Ospedaliero-Universitaria di BolognaLiver Transplant, Carbapenem-resistant Enterobacterales, CRE Colonization
Start: 2026-10-01End: 2029-09-30Target: 168Updated: 2026-08-12

Related Papers

Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme
Journal of Antimicrobial Chemotherapy2023-09-1316 citations
Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.
2021-08-1021 citations
Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
2020-08-0115 citations
Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers.
2019-05-2424 citations
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
2018-09-0161 citations
<i>In Vitro</i> Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens
Antimicrobial Agents and Chemotherapy2016-11-2224 citations
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients
Antimicrobial Agents and Chemotherapy2016-08-0958 citations
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Clinical Infectious Diseases2016-06-16338 citations
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
2016-04-20301 citations
Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects
Pharmacology Research & Perspectives2015-08-2542 citations